MGMT and central nervous system cancer: The prognostic value of this six-lncRNA signature is independent of the methylation status of O-6-methylguanine-DNA methyltransferase (MGMT) promoter, which can promote the treatment resistance of glioma cells to alkylating agent chemotherapy (Zhang X.Q. et al., 2013; Wick et al., 2014).